KNOWLEDGE BANK

Interviews

Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)

PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc

Articles

Incipient Biopharmaceutical Claims of Milk Derived Exosomes

Exosomes are bilayer nanoextracellular vehicles EVs that areproduced by endocytosis in mammalian cells Under physiological conditions they are involved in intercellular communication viaproteins lipids and RNAs With a size distribution of nm exosomes have been identified in various biofluids

Research Insights

Data-driven Discovery and Parameter Estimation of Mathematical Models in Biological Pattern Formation

Mathematical modeling has been utilized to explain biological pattern formation but the selections of models and parameters have been made empirically In the present study we propose a datadriven approach to validate the applicability of mathematical models

Case Studies

Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study

Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s

Techno Trends

Novel Avacincaptad Pegol Developed for Geographic Atrophy

IVERIC bio Inc developed avacincaptad pegol to treat geographic atrophy GA secondary to AgeRelated Macular Degeneration AMD Avacincaptad pegol ACP also known as Zimura a novel investigational complement C inhibitorhave shown positive results from the month prespecified primary endpoint data in the GATHER and GATHER pivotal

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

The Role of Genomics in Shaping the Future of Medicine

Smita Agrawal

Smita Agrawal holds a PhD in Chemical Engineering from the University of California, Berkeley. She has over 20 years of research experience in stem cell biology, neuroscience, immunology, genomics, oncology and real-world data. She currently serves as an independent consultant, offering strategic guidance and insights to life sciences companies on genomics, AI, and health care data applications.

2

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

3

Trump Tariff Tyranny and Pharma Preparedness

Dr. M Aamir Mirza

Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.

4

Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches

Saurabh Srivastava

Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.

 

Saurabh Shah

Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.

 

5

Generative AI and the New Era of Personalized Medicine

Uddalak Das

Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.

press releasesRead more...

Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases

Roche SIX RO ROP OTCQX RHHBY announced today the grand opening of the Roche Genentech Innovation Center Boston expanding Roche and Genentechs US research presence in one

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc NASDAQ RARE today announced that the US Food and Drug Administration FDA granted standard full approval of FAYUVI rebisufligene etisparvovechopf

Tenthpin Launches AI, IoMT-based Centre for Life Sciences Innovation Hub in Bengaluru

Switzerland based Tenthpin Management Consultants a global leader in management and technology consulting for Life Sciences companies has announced the launch of Innovation Hub in Bengaluru

Novo and Anthropic will collaborate to advance drug discovery with Claude

Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advance AIdriven software development

Leqembi® Pen subcutaneous formulation approved in Japan

BioArctic AB publs Nasdaq Stockholm BIOA B partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi known as Leqembi Pen in Japan has been approved as a new route of administration for the treatment of early Alzheimers disease

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Twist Bioscience Corporation NASDAQ TWST a midcap growth and value biotech company today announced an agreement with Lilly TuneLab a collaborative AIML drug discovery platform created by Eli Lilly and Company

EventsRead more...

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

29 - 01

Sep 2026

10th IPF Summit 2026

Boston, MA, USA

29 - 01

Sep 2026

Powtech Technopharm 2026

Nuremberg, Germany

30 - 01

Sep 2026

Pharma Launch Excellence Summit

Hyatt Regency Boston Harbor, B...

LATEST NEWSRead more...

Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody BsAb therapies for immunology and inflammation II diseases

Eisai and Biogen Receive Approval for LEQEMBI Pen for Early Alzheimer’s Disease

Eisai and Biogen have received approval in Japan for LEQEMBI Pen a subcutaneous SC formulation of lecanemab for the treatment of early Alzheimers disease AD

QurCan Therapeutics Enters into Collaboration with Lilly Advance Nucleic Acid Therapies for Nervous System Diseases

QurCan Therapeutics has entered into an exclusive research and collaboration agreement with Eli Lilly and Company to develop nucleic acid therapies for diseases affecting the central nervous system CNS and peripheral nervous system PNS

BostonGene Expands Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene has expanded its scientific collaboration with DanaFarber Cancer Institute to study the biological mechanisms involved in breast cancers associated with BRCA and BRCA mutations

Telix Receives Approval for Pixclara for Brain Cancer Imaging

Telix Pharmaceuticals has received approval from the US Food and Drug Administration FDA for Pixclara floretyrosine F or FFET a radioactive diagnostic drug used with positron emission tomography PET to image gliomas a type of brain cancer

Evonik Expands Biotechnology Manufacturing Capacity in Slovakia

Evonik has started construction of a biotechnology expansion at its Fermas site in Slovensk upa Slovakia